Literature DB >> 33361398

N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy.

Guixin Wu1,2, Jie Liu1,2, Shuiyun Wang3, Shiqin Yu4, Ce Zhang5, Dong Wang2, Mo Zhang2, Yaoyao Yang5, Lianming Kang2, Shihua Zhao4, Rutai Hui1, Yubao Zou6, Jizheng Wang7, Lei Song7,8.   

Abstract

OBJECTIVE: Elevated levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with heart failure-related death in hypertrophic cardiomyopathy (HCM), but the relationship between NT-proBNP level and sudden cardiac death (SCD) in HCM remains undefined.
METHODS: The study prospectively enrolled 977 unrelated patients with HCM with available NT-proBNP results who were prospectively enrolled and followed for 3.0±2.1 years. The Harrell's C-statistic under the receiver operating characteristic curve was calculated to evaluate discrimination performance. A combination model was constructed by adding NT-proBNP tertiles to the HCM Risk-SCD model. The correlation between log NT-proBNP level and cardiac fibrosis as measured by late gadolinium enhancement (LGE) or Masson's staining was analysed.
RESULTS: During follow-up, 29 patients had SCD. Increased log NT-proBNP levels were associated with an increased risk of SCD events (adjusted HR 22.27, 95% CI 10.93 to 65.63, p<0.001). The C-statistic of NT-proBNP in predicting SCD events was 0.80 (p<0.001). The combined model significantly improved the predictive efficiency of the HCM Risk-SCD model from 0.72 to 0.81 (p<0.05), with a relative integrated discrimination improvement of 0.002 (p<0.001) and net reclassification improvement of 0.67 (p<0.001). Furthermore, log NT-proBNP levels were significantly correlated with cardiac fibrosis as detected either by LGE (r=0.257, p<0.001) or by Masson's trichrome staining in the myocardium (r=0.198, p<0.05).
CONCLUSION: NT-proBNP is an independent predictor of SCD in patients with HCM and may help with risk stratification of this disease. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiac risk factors and prevention; hypertrophic cardiomyopathy; quality and outcomes of care

Mesh:

Substances:

Year:  2020        PMID: 33361398     DOI: 10.1136/heartjnl-2020-317701

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

1.  A risk score model to predict in-hospital mortality of patients with end-stage renal disease and acute myocardial infarction.

Authors:  Yuan Fu; Hao Sun; Zongsheng Guo; Li Xu; Xinchun Yang; Lefeng Wang; Kuibao Li; Mulei Chen; Yuanfeng Gao
Journal:  Intern Emerg Med       Date:  2020-10-19       Impact factor: 3.397

2.  Assessment of left atrial fibrosis progression in canines following rapid ventricular pacing using 3D late gadolinium enhanced CMR images.

Authors:  Nadia A Farrag; Rebecca E Thornhill; Frank S Prato; Allan C Skanes; Rebecca Sullivan; David Sebben; John Butler; Jane Sykes; Benjamin Wilk; Eranga Ukwatta
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

3.  Prognostic impact of mean heart rate by Holter monitoring on long-term outcome in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Gang Liu; Jian Shen; Yuan Yang; Xiang Li; Yuansong Zhu; Zhenxian Xiang; Hongbo Gan; Bi Huang; Suxin Luo
Journal:  Clin Res Cardiol       Date:  2021-02-06       Impact factor: 5.460

4.  Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy.

Authors:  Jie Liu; Dong Wang; Jieyun Ruan; Guixin Wu; Lianjun Xu; Wen Jiang; Jizheng Wang; Xiaolu Sun; Lianming Kang; Lei Song
Journal:  BMC Med       Date:  2022-01-26       Impact factor: 8.775

5.  Left ventricular strain patterns and their relationships with cardiac biomarkers in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction.

Authors:  Lisha Zhang; Yixuan Wan; Bo He; Lei Wang; Dongyong Zhu; Fabao Gao
Journal:  Front Cardiovasc Med       Date:  2022-10-04

6.  Cardiovascular disease training lessons learned during the COVID-19 pandemic: Need for change in training paradigm.

Authors:  Dakshin Gangadharamurthy
Journal:  J Nucl Cardiol       Date:  2020-09-10       Impact factor: 5.952

7.  N-terminal pro-brain natriuretic peptide and adverse outcomes in Chinese patients with hypertrophic cardiomyopathy.

Authors:  Zeng-Lei Zhang; Yan-Yan Xu; Zhen Qin; Yong-Zheng Lu; Tian-Ding Liu; Li Zhang; Jia-Hong Shangguan; Wei Wang; Jun-Nan Tang; Jin-Ying Zhang
Journal:  Biosci Rep       Date:  2022-01-28       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.